IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT05681351
- Locations
- 🇪🇸
Hospital Universitario de Jaen, Jaén, Spain
🇪🇸Hospital Abente y Lago, La Coruna, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Conditions
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 1400
- Registration Number
- NCT05667493
- Locations
- 🇮🇹
Azienda Ospedaliera - Universitaria Sant' Andrea, Roma, Italy
🇵🇹Unidade Local de Saúde de São José, E. P. E - Hospital de Santa Marta, Lisbon, Portugal
🇪🇸Complejo Hospitalario Universitario de Santiago (CHUS), Santiago De Compostela, Spain
Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease
- Conditions
- Pelizaeus-Merzbacher Disease
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05659901
- Locations
- 🇳🇱
Ionis Investigative Site, Amsterdam, Netherlands
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
- Conditions
- Cardiovascular DiseasesHypertriglyceridemiaAtherosclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 1478
- Registration Number
- NCT05610280
- Locations
- 🇮🇹
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome, Italy
🇳🇱Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
🇵🇱FutureMeds Sp. z o.o, Wrocław, Poland
A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT05579860
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 446
- Registration Number
- NCT05552326
- Locations
- 🇺🇸
Clinical Investigation Specialists Inc., Kenosha, Wisconsin, United States
🇺🇸NRC Research Institute, Los Angeles, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT05392114
- Locations
- 🇬🇧
Ionis Investigative Site, London, United Kingdom
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
- Conditions
- HypertriglyceridemiaAtherosclerotic Cardiovascular DiseaseSevere Hypertriglyceridemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT05355402
- Locations
- 🇺🇸
Main Street Physicians Care Waterway, Little River, South Carolina, United States
🇨🇦Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦Clinique des Maladies Lipidiques de Quebec Inc., Quebec, Canada
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05337878
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05314439
- Locations
- 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸Altasciences, Overland Park, Kansas, United States
🇺🇸Altasciences - Los Angeles, Cypress, California, United States